New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:08 EDTARWRArrowHead Research publishes results regarding company's Dynamic Polyconjugate
Arrowhead Research announced the publication of data demonstrating that high level target gene knockdown with low doses of cholesterol-siRNA is possible in non-human primates using the company's Dynamic Polyconjugate delivery system and a novel co-injection strategy. This new delivery approach dramatically increases the efficacy of cholesterol-siRNA and, together with the co-injection strategy, simplifies the manufacturing process to enable a commercially scalable delivery vehicle for RNAi therapeutics. The company is using this strategy and a next generation DPC polymer in ARC-520, its hepatitis B clinical candidate. The paper titled, "Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated siRNAs in vivo," was published online ahead of print in the journal Nucleic Acid Therapeutics to be featured in the December issue
News For ARWR From The Last 14 Days
Check below for free stories on ARWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
14:54 EDTARWRArrowhead Research November volatility elevated into Phase IIb trial data
Subscribe for More Information
07:36 EDTARWRArrowhead outlook positive, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use